CPD

Across TCGA pan-cancer cohorts, CPD Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CPD data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CPD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CPD expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

HNSC, ESCA, and PRAD are the cancer types where CPD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.075	0.770	<.001	48	view →
ESCA	OS	Median	III,IV	0.130	0.574	.011	6	view →
PRAD	DFS	Median	All	0.238	0.775	.044	4	view →
STAD	DFS	Median	III,IV	1.000	0.318	.046	3	view →
BLCA	OS	Median	III,IV	0.141	0.581	.018	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CPD–HNSC (OS)

Open the HNSC breakdown →